{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:18:32Z","timestamp":1795195112497,"version":"4.10.3"},"reference-count":100,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antileukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise for strengthening immune control in CML but requires the identification of CML-associated targets. In this study, we used a mass spectrometry\u2013based approach to identify naturally presented HLA class I\u2013 and class II\u2013restricted peptides in primary CML samples. Comparative HLA ligandome profiling using a comprehensive dataset of different hematological benign specimens and samples from CML patients in deep molecular remission delineated a panel of novel frequently presented CML-exclusive peptides. These nonmutated target antigens are of particular relevance because our extensive data-mining approach suggests the absence of naturally presented BCR-ABL\u2013 and ABL-BCR\u2013derived HLA-restricted peptides and the lack of frequent tumor-exclusive presentation of known cancer\/testis and leukemia-associated antigens. Functional characterization revealed spontaneous T-cell responses against the newly identified CML-associated peptides in CML patient samples and their ability to induce multifunctional and cytotoxic antigen-specific T cells de novo in samples from healthy volunteers and CML patients. Thus, these antigens are prime candidates for T-cell\u2013based immunotherapeutic approaches that may prolong TKI-free survival and even mediate cure of CML patients.<\/jats:p>","DOI":"10.1182\/blood-2018-07-866830","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T03:55:12Z","timestamp":1544500512000},"page":"550-565","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy"],"prefix":"10.1182","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8107-0419","authenticated-orcid":false,"given":"Tatjana","family":"Bilich","sequence":"first","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-8481","authenticated-orcid":false,"given":"Annika","family":"Nelde","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-0073","authenticated-orcid":false,"given":"Leon","family":"Bichmann","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-9778","authenticated-orcid":false,"given":"Malte","family":"Roerden","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Clinical Cooperation Unit Translational Immunology, German Cancer Consortium, German Cancer Research Center (DKFZ) partner site T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Kowalewski","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Immatics Biotechnologies, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Schuster","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Immatics Biotechnologies, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-5463","authenticated-orcid":false,"given":"Chih-Chiang","family":"Tsou","sequence":"additional","affiliation":[{"name":"Immatics US, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0808-8097","authenticated-orcid":false,"given":"Ana","family":"Marcu","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2828-4706","authenticated-orcid":false,"given":"Marian C.","family":"Neidert","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-3911","authenticated-orcid":false,"given":"Maren","family":"L\u00fcbke","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Rieth","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-3529","authenticated-orcid":false,"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen, Aachen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-3723","authenticated-orcid":false,"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule (RWTH) Aachen, Aachen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-2385","authenticated-orcid":false,"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-3894","authenticated-orcid":false,"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[{"name":"Clinical Cooperation Unit Translational Immunology, German Cancer Consortium, German Cancer Research Center (DKFZ) partner site T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet K.","family":"Peper","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-3901","authenticated-orcid":false,"given":"Reinhild","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-4598","authenticated-orcid":false,"given":"Oliver","family":"Kohlbacher","sequence":"additional","affiliation":[{"name":"Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Quantitative Biology Center, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"Biomolecular Interactions, Max-Planck-Institute for Developmental Biology, T\u00fcbingen, Germany;"},{"name":"Institute for Translational Bioinformatics, University Hospital T\u00fcbingen, T\u00fcbingen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1614-2647","authenticated-orcid":false,"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"German Cancer Consortium, DKFZ partner site T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-1437","authenticated-orcid":false,"given":"Stefan","family":"Stevanovi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology, Department of Immunology, University of T\u00fcbingen, T\u00fcbingen, Germany;"},{"name":"German Cancer Consortium, DKFZ partner site T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-7391","authenticated-orcid":false,"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2020073012064377800_B1","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1073\/pnas.0900653106","article-title":"Charting the molecular network of the drug target Bcr-Abl","volume":"106","author":"Brehme","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020073012064377800_B2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2020073012064377800_B3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"28","key":"2020073012064377800_B4","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020073012064377800_B5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2020073012064377800_B6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2020073012064377800_B7","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1200\/jco.2014.32.15_suppl.7081","article-title":"Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow up of the PACE trial","volume":"32","author":"Kantarjian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020073012064377800_B8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"2020073012064377800_B9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020073012064377800_B10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"2020073012064377800_B11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2020073012064377800_B12","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020073012064377800_B13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","article-title":"Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","author":"Sopper","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020073012064377800_B14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020073012064377800_B15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2017.348","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"32","author":"Sch\u00fctz","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2020073012064377800_B16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2020073012064377800_B17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020073012064377800_B18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2020073012064377800_B19","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"2020073012064377800_B20","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2020073012064377800_B21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"2020073012064377800_B22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2020073012064377800_B23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2020073012064377800_B24"},{"issue":"3","key":"2020073012064377800_B25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2020073012064377800_B26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020073012064377800_B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.coi.2008.04.009","article-title":"WT1 peptide vaccine for the treatment of cancer","volume":"20","author":"Oka","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"2020073012064377800_B28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"21","key":"2020073012064377800_B29","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2020073012064377800_B30","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1172\/JCI92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J Clin Invest"},{"issue":"3","key":"2020073012064377800_B31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.smim.2010.02.003","article-title":"Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation","volume":"22","author":"O\u2019Reilly","year":"2010","journal-title":"Semin Immunol"},{"issue":"8","key":"2020073012064377800_B32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"2020073012064377800_B33","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"6324","key":"2020073012064377800_B34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/351290a0","article-title":"Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules","volume":"351","author":"Falk","year":"1991","journal-title":"Nature"},{"issue":"32","key":"2020073012064377800_B35","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020073012064377800_B36","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/1078-0432.CCR-11-3185","article-title":"Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response","volume":"18","author":"Godet","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"46","key":"2020073012064377800_B37","doi-asserted-by":"crossref","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2020073012064377800_B38","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) [published corrections appear in Proc Natl Acad Sci USA 2015;112(45):E6254-E6256 and E6258-E6260]","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2020073012064377800_B39","doi-asserted-by":"crossref","first-page":"e1011527","DOI":"10.1080\/2162402X.2015.1011527","article-title":"Antileukemia T-cell responses in CLL - we don\u2019t need no aberration","volume":"4","author":"Kowalewski","year":"2015","journal-title":"OncoImmunology"},{"issue":"3","key":"2020073012064377800_B40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/leu.2014.233","article-title":"Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy [published correction appears in Leukemia 2016;30(40):1003-1004]","volume":"29","author":"Berlin","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2020073012064377800_B41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"issue":"27","key":"2020073012064377800_B42","doi-asserted-by":"crossref","first-page":"43915","DOI":"10.18632\/oncotarget.14918","article-title":"A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and \u201cpan-leukemia\u201d antigens","volume":"8","author":"Backert","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"2020073012064377800_B43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.x","article-title":"Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia","volume":"80","author":"Greiner","year":"2008","journal-title":"Eur J Haematol"},{"issue":"11","key":"2020073012064377800_B44","first-page":"2675","article-title":"A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia","volume":"59","author":"Molldrem","year":"1999","journal-title":"Cancer Res"},{"issue":"5","key":"2020073012064377800_B45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","article-title":"Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells","volume":"111","author":"Molldrem","year":"2003","journal-title":"J Clin Invest"},{"issue":"24 Pt 1","key":"2020073012064377800_B46","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1158\/1078-0432.CCR-05-1314","article-title":"T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms\u2019 tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization","volume":"11","author":"Rezvani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020073012064377800_B47","first-page":"693","article-title":"Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes","volume":"10","author":"Greco","year":"1996","journal-title":"Leukemia"},{"issue":"3","key":"2020073012064377800_B48","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.V91.3.977","article-title":"Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia","volume":"91","author":"Nieda","year":"1998","journal-title":"Blood"},{"issue":"10","key":"2020073012064377800_B49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2404354","article-title":"BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes","volume":"20","author":"Kessler","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2020073012064377800_B50","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","article-title":"Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses","volume":"95","author":"Pinilla-Ibarz","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2020073012064377800_B51","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","article-title":"A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia","volume":"103","author":"Cathcart","year":"2004","journal-title":"Blood"},{"issue":"9460","key":"2020073012064377800_B52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"2020073012064377800_B53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.exphem.2008.05.002","article-title":"Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens","volume":"36","author":"Fei","year":"2008","journal-title":"Exp Hematol"},{"issue":"5b 5B","key":"2020073012064377800_B54","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","article-title":"Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling","volume":"12","author":"Chen","year":"2008","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2020073012064377800_B55","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2020073012064377800_B56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"issue":"4","key":"2020073012064377800_B57","doi-asserted-by":"crossref","first-page":"e1316438","DOI":"10.1080\/2162402X.2017.1316438","article-title":"HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy","volume":"7","author":"Nelde","year":"2018","journal-title":"OncoImmunology"},{"key":"2020073012064377800_B58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-62703-218-6_12","article-title":"Biochemical large-scale identification of MHC class I ligands","volume":"960","author":"Kowalewski","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2020073012064377800_B59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo","year":"1993","journal-title":"Blood"},{"issue":"3","key":"2020073012064377800_B60","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.leu.2401703","article-title":"Peptides spanning the junctional region of both the abl\/bcr and the bcr\/abl fusion proteins bind common HLA class I molecules","volume":"14","author":"Berke","year":"2000","journal-title":"Leukemia"},{"issue":"11","key":"2020073012064377800_B61","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmeth1113","article-title":"Semi-supervised learning for peptide identification from shotgun proteomics datasets","volume":"4","author":"K\u00e4ll","year":"2007","journal-title":"Nat Methods"},{"key":"2020073012064377800_B62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-60327-118-9_5","article-title":"SYFPEITHI: database for searching and T-cell epitope prediction","volume":"409","author":"Schuler","year":"2007","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2020073012064377800_B63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med"},{"issue":"1","key":"2020073012064377800_B64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-008-0341-z","article-title":"NetMHCpan, a method for MHC class I binding prediction beyond humans","volume":"61","author":"Hoof","year":"2009","journal-title":"Immunogenetics"},{"issue":"1","key":"2020073012064377800_B65","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/ncomms2610","article-title":"Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons","volume":"4","author":"Sturm","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"2020073012064377800_B66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ijc.26365","article-title":"Promiscuous survivin peewptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients","volume":"131","author":"Widenmeyer","year":"2012","journal-title":"Int J Cancer"},{"issue":"10","key":"2020073012064377800_B67","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.4049\/jimmunol.171.10.4974","article-title":"Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC\/anti-CD28-coated microspheres","volume":"171","author":"Walter","year":"2003","journal-title":"J Immunol"},{"issue":"9","key":"2020073012064377800_B68","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-013-1454-2","article-title":"Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer","volume":"62","author":"Neumann","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2020073012064377800_B69","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-007-0360-x","article-title":"Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells","volume":"57","author":"Rudolf","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"2020073012064377800_B70","first-page":"2750","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"126","author":"Nelde","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"2020073012064377800_B71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo","volume":"285","author":"Hermans","year":"2004","journal-title":"J Immunol Methods"},{"issue":"3","key":"2020073012064377800_B72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nbt.2839","article-title":"ProteomeXchange provides globally coordinated proteomics data submission and dissemination","volume":"32","author":"Vizca\u00edno","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2020073012064377800_B73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"Database issue","key":"2020073012064377800_B74","doi-asserted-by":"crossref","first-page":"D405","DOI":"10.1093\/nar\/gku938","article-title":"The immune epitope database (IEDB) 3.0","volume":"43","author":"Vita","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"2020073012064377800_B75","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2020073012064377800_B76","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"GTEx Consortium","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"2020073012064377800_B77","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","article-title":"Antigens in chronic myeloid leukemia: implications for vaccine development","volume":"60","author":"Smahel","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"Database issue","key":"2020073012064377800_B78","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonz\u00e1lez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"6684","key":"2020073012064377800_B79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"issue":"6925","key":"2020073012064377800_B80","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"issue":"15","key":"2020073012064377800_B81","doi-asserted-by":"crossref","first-page":"8633","DOI":"10.1073\/pnas.96.15.8633","article-title":"CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma [published correction appears in Proc. Natl Acad Sci USA 2000;97(5):2397]","volume":"96","author":"Mumberg","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020073012064377800_B82","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2011-11-394395","article-title":"Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia","volume":"120","author":"Greiner","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2020073012064377800_B83","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","article-title":"CD4 cells can be more efficient at tumor rejection than CD8 cells","volume":"109","author":"Perez-Diez","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2020073012064377800_B84","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ni1105","article-title":"CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection","volume":"5","author":"Sun","year":"2004","journal-title":"Nat Immunol"},{"issue":"6184","key":"2020073012064377800_B85","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"7","key":"2020073012064377800_B86","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/ijc.29909","article-title":"Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation","volume":"138","author":"Casalegno-Gardu\u00f1o","year":"2016","journal-title":"Int J Cancer"},{"issue":"11","key":"2020073012064377800_B87","doi-asserted-by":"crossref","first-page":"e0142310","DOI":"10.1371\/journal.pone.0142310","article-title":"Spontaneous immunity against the receptor tyrosine kinase ROR1 in patients with chronic lymphocytic leukemia","volume":"10","author":"Hojjat-Farsangi","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"2020073012064377800_B88","first-page":"17","article-title":"Immunomodulatory effects of tyrosine kinase inhibitors","volume":"1","author":"Kreutzman","year":"2013","journal-title":"Int Trends Immun"},{"key":"2020073012064377800_B89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.08.005","article-title":"HLA-G molecules and clinical outcome in chronic myeloid leukemia","volume":"61","author":"Caocci","year":"2017","journal-title":"Leuk Res"},{"issue":"12","key":"2020073012064377800_B90","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.exphem.2010.09.004","article-title":"Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive","volume":"38","author":"Rojas","year":"2010","journal-title":"Exp Hematol"},{"issue":"7463","key":"2020073012064377800_B91","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer [published correction appears in Nature 2013:502(7470):258]","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"11","key":"2020073012064377800_B92","doi-asserted-by":"crossref","first-page":"a028829","DOI":"10.1101\/cshperspect.a028829","article-title":"Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Neoantigens: Nothing new in spite of the name","volume":"10","author":"Finn","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2020073012064377800_B93","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"issue":"7662","key":"2020073012064377800_B94","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"3","key":"2020073012064377800_B95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12936","article-title":"Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry","volume":"154","author":"Freudenmann","year":"2018","journal-title":"Immunology"},{"key":"2020073012064377800_B96","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","article-title":"Mass spectrometry-based antigen discovery for cancer immunotherapy","volume":"41","author":"Bassani-Sternberg","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2020073012064377800_B97","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1074\/mcp.M600310-MCP200","article-title":"Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface","volume":"6","author":"Weinzierl","year":"2007","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"2020073012064377800_B98","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.20071985","article-title":"The MHC class I peptide repertoire is molded by the transcriptome","volume":"205","author":"Fortier","year":"2008","journal-title":"J Exp Med"},{"issue":"3","key":"2020073012064377800_B99","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1074\/mcp.M114.042812","article-title":"Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation","volume":"14","author":"Bassani-Sternberg","year":"2015","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"2020073012064377800_B100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00401-018-1836-9","article-title":"The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy","volume":"135","author":"Neidert","year":"2018","journal-title":"Acta Neuropathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/6\/550\/1750615\/blood866830.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/6\/550\/1750615\/blood866830.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:40:29Z","timestamp":1596148829000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/6\/550\/260571\/The-HLA-ligandome-landscape-of-chronic-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-866830","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]}}}